Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cell Physiol Biochem ; 35(2): 755-66, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25613909

RESUMO

BACKGROUND: Thyroid hormones (THs) are key regulators of cardiac physiology as well as modulators of different cellular signals including the sphingomyelin/ceramide pathway. The objective of this study was to examine the effect of hyperthyroidism on the metabolism of sphingolipids in the muscle heart. METHODS: Male Wistar rats were treated for 10 days with triiodothyronine (T3) at a dose of 50µg/100g of body weight. Animals were then anaesthetized and samples of the left ventricle were excised. RESULTS: We have demonstrated that prolonged, in vivo, T3 treatment increased the content of sphinganine (SFA), sphingosine (SFO), ceramide (CER) and sphingomyelin (SM), but decreased the level of sphingosine-1-phosphate (S1P) in cardiac muscle. Accordingly, the changes in sphingolipids content were accompanied by a lesser activity of neutral sphingomyelinase and without significant changes in ceramidases activity. Hyperthyroidism also induced activation of AMP-activated protein kinase (AMPK) with subsequently increased expression of mitochondrial proteins: cytochrome c oxidase IV (COX IV), ß-hydroxyacyl-CoA dehydrogenase (ß-HAD), carnityne palmitoyltransferase I (CPT I) and nuclear peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α). CONCLUSIONS: We conclude that prolonged T3 treatment increases sphingolipids metabolism which is reflected by higher concentration of SFA and CER in heart muscle. Furthermore, hyperthyroidism-induced increase in heart sphingomyelin (SM) concentration might be one of the mechanisms underlying maintenance of CER at relatively low level by its conversion to SM together with decreased S1P content.


Assuntos
Ceramidas/metabolismo , Hipertireoidismo/metabolismo , Miocárdio/metabolismo , Esfingomielinas/metabolismo , Tri-Iodotironina/administração & dosagem , Animais , Ceramidases/metabolismo , Modelos Animais de Doenças , Hipertireoidismo/induzido quimicamente , Hipertireoidismo/enzimologia , Lisofosfolipídeos/metabolismo , Masculino , Ratos , Ratos Wistar , Esfingomielina Fosfodiesterase/metabolismo , Esfingosina/análogos & derivados , Esfingosina/metabolismo , Tri-Iodotironina/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...